Emerson Electric Co. (EMR) and Rockwell Automation, Inc. (ROK) rank among the most closely watched industrial automation stocks. Both sit at the intersection of electrification, reshoring, and AI-enabled manufacturing. Their business models and recent results, however, have taken different paths, and the latest quarterly reports sent their shares in opposite directions. This comparison helps clarify how their positioning and momentum differ within the sector.
Emerson Electric, based in St. Louis, Missouri, operates as a diversified global automation and technology company across industrial, commercial, and residential markets. It has shifted its portfolio toward higher-margin automation and software, with the AspenTech integration now complete ahead of schedule. The company reports across Software & Systems, Intelligent Devices, and Safety & Productivity groups.
Recent results showed resilient demand. Underlying orders rose by a double-digit percentage in the latest quarter, supported by long-cycle projects in power generation, LNG, semiconductors, and aerospace & defense. Management raised its full-year outlook for sales, earnings, and free cash flow, while noting ongoing softness in Europe and China. The stock's performance has reflected this broad-based strength and more consistent top-line growth alongside expanding segment margins. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Rockwell Automation, headquartered in Milwaukee, Wisconsin, specializes in industrial automation and digital transformation, with a focus on factory automation controls, drives, software, and connected services. Its exposure leans more toward discrete manufacturing and process industries such as automotive, food and beverage, mining, and energy.
The company posted strong profitability gains, with enterprise operating margin hitting its long-term target ahead of schedule and adjusted EPS rising sharply year over year. The Software & Control segment grew solidly, led by the Logix platform. Yet organic ARR growth slowed, and revenue missed consensus partly due to tariff-related refund accounting. Shares declined sharply after the report, as investors focused on the trajectory of recurring revenue rather than the earnings beat.
Although both companies operate in industrial automation, their profiles differ. EMR is larger and more diversified, with a substantial software component, wider geographic reach, and significant exposure to energy, power, and process markets. ROK remains more concentrated on discrete factory automation and shorter-cycle demand tied to manufacturing activity.
Growth drivers also vary. EMR has benefited from investment in electrification, energy security, and reshoring, which produced accelerating orders and an expanding project funnel. ROK has seen gains from new products and share growth in its Logix platform, along with traction in semiconductors and data centers, but its recurring-revenue growth has decelerated.
Risk factors diverge as well. EMR contends with softness in Europe and China and greater exposure to cyclical energy and process projects. ROK faces sensitivity to manufacturing capital spending, component-cost inflation, and the market's reaction to slowing ARR growth despite strong margins. Sentiment has generally favored EMR for its broadening demand, while ROK drew a more cautious response.
Based on trend consistency, breadth of demand, and relative positioning, Tickeron's AI currently favors EMR over ROK. Emerson's accelerating order growth, rising project funnel, diversified end-market mix, and raised outlook point to more stable momentum. Rockwell's margin gains are offset by decelerating recurring-revenue growth and a share-price reaction that reflects investor concern about sustainability. This view is probabilistic and reflects the current balance of fundamentals rather than a guarantee of future results.
When evaluating names like these, I sometimes review Tickeron’s Trending AI Robots to observe how automated strategies are positioned across the market. The section highlights bots with the strongest alignment to current conditions, offering a data-driven view of trading approaches without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EMR saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 60 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 66%.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 219 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 151 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 19 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 60 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 27 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.444) is normal, around the industry mean (3.761). P/E Ratio (35.370) is within average values for comparable stocks, (36.274). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.032) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery